20 October 2021 - Lunch meeting - Login for venue
The UK response to the COVID pandemic has established our global reputation as a scientific leader in life sciences. Key to this success has been the collaborative approach between the scientific community, the pharmaceutical industry, and the NHS. The recently published Life Sciences Vision sets out how the Government intends to build on this to position the UK as the leading global hub for life sciences. The challenges are to provide the right incentives for companies to work with the scientific community to develop and deliver new drugs and therapies in the UK, and to do this within an affordable budget, while ensuring that patients have access to new and innovative medicines. This policy workshop will look at existing hurdles and how these could be addressed by collaborative planning, streamlining approval procedures, and by new approaches to the access and uptake of new medicines. The expert panel will discuss the key policy initiatives needed and what the benefits might be.
Michael Finn, Partner, Pinsent Masons
Sponsors: IF Project